Format

Send to

Choose Destination
Mol Pharmacol. 2018 Aug;94(2):850-861. doi: 10.1124/mol.118.111948. Epub 2018 May 16.

Small-Molecule Positive Allosteric Modulators of the β2-Adrenoceptor Isolated from DNA-Encoded Libraries.

Author information

1
Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O., G.H., M.V., T.F.); Department of Medicinal Chemistry, School of Pharmaceutical Engineering and Life Science, Changzhou University, Changzhou, Jiangsu, China (L.J., S.Z., X.C.); and Department of Biology, Duke University, Durham, North Carolina (P.J.S.).
2
Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O., G.H., M.V., T.F.); Department of Medicinal Chemistry, School of Pharmaceutical Engineering and Life Science, Changzhou University, Changzhou, Jiangsu, China (L.J., S.Z., X.C.); and Department of Biology, Duke University, Durham, North Carolina (P.J.S.) lefko001@receptor-biol.duke.edu.

Abstract

Conventional drug discovery efforts at the β2-adrenoceptor (β2AR) have led to the development of ligands that bind almost exclusively to the receptor's hormone-binding orthosteric site. However, targeting the largely unexplored and evolutionarily unique allosteric sites has potential for developing more specific drugs with fewer side effects than orthosteric ligands. Using our recently developed approach for screening G protein-coupled receptors (GPCRs) with DNA-encoded small-molecule libraries, we have discovered and characterized the first β2AR small-molecule positive allosteric modulators (PAMs)-compound (Cmpd)-6 [(R)-N-(4-amino-1-(4-(tert-butyl)phenyl)-4-oxobutan-2-yl)-5-(N-isopropyl-N-methylsulfamoyl)-2-((4-methoxyphenyl)thio)benzamide] and its analogs. We used purified human β2ARs, occupied by a high-affinity agonist, for the affinity-based screening of over 500 million distinct library compounds, which yielded Cmpd-6. It exhibits a low micro-molar affinity for the agonist-occupied β2AR and displays positive cooperativity with orthosteric agonists, thereby enhancing their binding to the receptor and ability to stabilize its active state. Cmpd-6 is cooperative with G protein and β-arrestin1 (a.k.a. arrestin2) to stabilize high-affinity, agonist-bound active states of the β2AR and potentiates downstream cAMP production and receptor recruitment of β-arrestin2 (a.k.a. arrestin3). Cmpd-6 is specific for the β2AR compared with the closely related β1AR. Structure-activity studies of select Cmpd-6 analogs defined the chemical groups that are critical for its biologic activity. We thus introduce the first small-molecule PAMs for the β2AR, which may serve as a lead molecule for the development of novel therapeutics. The approach described in this work establishes a broadly applicable proof-of-concept strategy for affinity-based discovery of small-molecule allosteric compounds targeting unique conformational states of GPCRs.

PMID:
29769246
PMCID:
PMC6022804
DOI:
10.1124/mol.118.111948
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center